Clinical Efficacy and Adverse Reaction Analysis of Anti-infective Drugs Combined with Glucocorticoids in the Treatment of Children with Severe Pneumonia in Pediatric Emergency
Xu Shan
Hubei Third People's Hospital, Emergency Pediatrics Hubei Wuhan 430033
Abstract：Objective To investigate the clinical efficacy and incidence of adverse reactions of anti-infective drugs combined with glucocorticoids in the treatment of children with severe pneumonia in pediatric emergency,and to provide a reference for optimizing clinical treatment regimens. Methods A total of 90 children with severe pneumonia admitted to the pediatric emergency department of our hospital from July 2025 to December were selected and randomly divided into the control group and the observation group with 45 cases in each group using a random number table method.The control group was treated with anti-infective drugs alone,while the observation group was treated with glucocorticoids on the basis of the control group.Both groups completed standardized treatment and follow-up.The disappearance time of clinical symptoms and signs,laboratory inflammatory indicators before and after treatment,absorption of pulmonary lesions,respiratory function indicators,clinical efficacy,length of hospital stay and incidence of adverse reactions were compared between the two groups. Results The disappearance time of fever,cough,dyspnea and absorption time of pulmonary rales in the observation group were significantly shorter than those in the control group(P<0.05).After treatment,the peripheral blood white blood cell count(WBC),C-reactive protein(CRP) and procalcitonin(PCT) in both groups were significantly lower than those before treatment,and the levels of each indicator in the observation group were significantly lower than those in the control group(P<0.05).The complete absorption rate of pulmonary lesions in the observation group(71.11%) was significantly higher than that in the control group(40.00%)(P<0.05).After treatment,the blood oxygen saturation(SpO2),forced vital capacity(FVC),forced expiratory volume in the first second(FEV1) and FEV1/FVC in the observation group were significantly better than those in the control group(P<0.05).The total clinical effective rate and clinical cure rate in the observation group were significantly higher than those in the control group(P<0.05),and the length of hospital stay was significantly shorter than that in the control group(P<0.05).The adverse reactions in both groups were mainly mild to moderate gastrointestinal reactions and electrolyte disturbances,with no severe adverse reactions occurred.There was no statistically significant difference in the total incidence of adverse reactions between the observation group(11.11%) and the control group(15.56%)(P>0.05). Conclusion Anti-infective drugs combined with glucocorticoids in the treatment of children with severe pneumonia in pediatric emergency can rapidly relieve clinical symptoms,effectively reduce inflammatory indicators,promote the absorption of pulmonary lesions and the recovery of respiratory function,improve clinical efficacy and shorten the length of hospital stay.Moreover,standardized medication does not increase the risk of adverse reactions with good medication safety,which is worthy of clinical promotion and application.
许珊. 抗感染药物联合糖皮质激素在儿科急诊重症肺炎患儿治疗中的临床效果及不良反应分析[J]. 哈尔滨医药, 2026, 46(4): 30-34.
Xu Shan. Clinical Efficacy and Adverse Reaction Analysis of Anti-infective Drugs Combined with Glucocorticoids in the Treatment of Children with Severe Pneumonia in Pediatric Emergency. journal1, 2026, 46(4): 30-34.
[1] Yang S,Lu S,Guo Y,et al.A comparative study of general and severe mycoplasma pneumoniae pneumonia in children.BMC Infect Dis.2024 Apr 26;24(1):449. [2] Rueda ZV,Aguilar Y,Maya MA,et al.Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents.BMC Pediatr.2022 Mar 31;22(1):169. [3] Chen D,Cao L,Li W.Etiological and clinical characteristics of severe pneumonia in pediatric intensive care unit(PICU).BMC Pediatr.2023 Jul 15;23(1):362. [4] 周贝贝,李洁,张萌.小儿重症肺炎预后转归与MPV/PLT及炎症反应相关指标的关系及临床价值研究[J].河北医学,2025,31(06):969-973. [5] 陶桃,黄国兰,屠丹丽.小儿重症肺炎不同药物治疗下的严重并发症以及影响患儿死亡的危险因素分析[J].中国优生与遗传杂志,2023,31(8):1711-1715. [6] 郑奎,李曾妮,韩周玻.儿童重症肺炎支原体肺炎的发病机制及治疗研究进展[J].临床肺科杂志,2025,30(09):1439-1443. [7] 付红敏,陆权.关注重症肺炎——兼谈儿童呼吸与危重症医学结合发展的一点思考[J].中国实用儿科杂志,2022,37(2):88-91. [8] 中国妇幼保健协会儿童变态反应专业委员会,《中国实用儿科杂志》编辑委员会,邹映雪,赵顺英,刘瀚旻,刘薇,陆权.儿童重症肺炎临床预警及早期决策专家共识[J].中国实用儿科杂志,2023,38(3):177-182. [9] 李静,王燕萍,冯正录.探讨吸入用糖皮质激素在儿童重症肺炎中的合理使用[J].中国处方药,2024,22(1):63-66. [10] See XY,Wang TH,Chang YC,Lo J,et al.Impact of different corticosteroids on severe community-acquired pneumonia:a systematic review and meta-analysis.BMJ Open Respir Res.2024 Jan 22;11(1):e002141. [11] 中华人民共和国国家卫生健康委员会.儿童社区获得性肺炎诊疗规范(2019年版)[J].中国实用乡村医生杂志,2019,26(4):6-13. [12] 贾苗辉,张亚芳,冀虎,等.应用不同剂量的甲泼尼龙辅助治疗小儿重症肺炎的临床疗效及分析评价[J].现代消化及介入诊疗,2022(S01):0736-0736. [13] 李爱玲. 甲泼尼龙联合抗生素治疗重症肺炎的临床效果及安全性[J].湖南中医药大学学报,2020(S02):0126-0128. [14] 沙娟娟,王丽娟.甲泼尼龙联合乌司他丁治疗重症帕金森病合并重症肺炎患者的疗效观察[J].检验医学与临床,2020,17(17):2504-2506,2510. [15] 张蕊,王淞,成艳丽.甲泼尼龙联合抗生素治疗重症肺炎的临床观察[J].贵州医药,2021,045(011):1727-1728. [16] 易洁梅,梁敏清,张锦丽,盘秋明.糖皮质激素在儿童呼吸道疾病中的应用状况与安全性分析[J].中国药业,2016,25(13):89-92. [17] 赵全凤,董志,路晓钦.糖皮质激素在呼吸系统疾病中应用的循证医学研究进展[J].中国临床药理学与治疗学,2015,50(10):1194-1200.
2026, Vol. 46 
